News

Releases included below may include references to both on-label and off-label usage of the HeartLight® Endoscopic Ablation System.
11
Jan
2024
11 Jan 2024

CardioFocus Acquires Electrophysiology Division of Galvanize Therapeutics

CardioFocus, Inc., announced the acquisition of Galvanize Therapeutics’ Electrophysiology Technology division. Notable assets included in the acquisition are the CENTAURI System pulsed electric field generator, which is CE marked and commercially available in the EU and the UK, and the QuickShot™ catheter ablation system, currently in development.

19
Jul
2022
19 Jul 2022

CardioFocus Announces Pulsed Field Ablation Milestones

MARLBOROUGH, Mass., July 19, 2022 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (Afib), today announced several milestones toward the development of a next generation pulse field ablation (PFA) technology for treatment of AFib, including the formation of a clinical advisory board, filing of key patents and […]

14
Sep
2021
14 Sep 2021

CardioFocus Announces Agreement to Acquire Intellectual Property

MARLBOROUGH, Mass., September 14, 2021 – CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (AFib), announced today that it has entered into an agreement with IsoLase Ltd. to acquire IsoLase’s patent portfolio.

12
Aug
2021
12 Aug 2021

CardioFocus to Participate at the 6th Annual Needham Virtual Med Tech & Diagnostics 1×1 Conference

MARLBOROUGH, Mass., August 12, 2021 – CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that its management team will attend investor meetings at the 6th Annual Needham Virtual Med Tech & Diagnostics 1×1 Conference from August 16-17, 2021.

19
Jul
2021
19 Jul 2021

CardioFocus to Exhibit and Present Data Supporting HeartLight X3 System at Heart Rhythm 2021

MARLBOROUGH, Mass., July 19, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced its participation and presence at the Heart Rhythm 2021 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, July 28-31, 2021.

29
Jun
2021
29 Jun 2021

CardioFocus Appoints Stephan Ogilvie as Chief Financial Officer

MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the appointment of Stephan Ogilvie as its Chief Financial Officer.

25
Jun
2021
25 Jun 2021

Cardiofocus® Receives Regulatory Approval to Market HeartLight X3 System in Japan

CardioFocus, Inc., a medical device company, dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that the Japanese Ministry of Health, Labor and Welfare (“MHLW”) has approved the company’s HeartLight X3 System for marketing in Japan.

04
Jun
2021
04 Jun 2021

CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China

MARLBOROUGH, Mass., June 2, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (AFib), announced today that it has entered into a licensing and distribution agreement with China Grand Pharmaceutical (Grand Pharma). The agreement provides a license to Grand Pharma to seek regulatory approvals and commercialize the HeartLight X3 System in China, Hong Kong and Macau. […]

16
Mar
2021
16 Mar 2021

CardioFocus® Invited To Participate At The Oppenheimer 31st Annual Healthcare Conference

MARLBOROUGH, Mass., March 16, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer and President Burke T. Barrett will present at the Oppenheimer 31st Annual Healthcare Conference, being held virtually March 16-18, 2021.

25
Feb
2021
25 Feb 2021

CardioFocus® Announces The Publication Of HeartLight X3 Pivotal Study Data

MARLBOROUGH, Mass., Feb. 25, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that results from its HeartLight® X3 Pivotal Study were published in the premier journal Circulation: Arrhythmia and Electrophysiology (CircEP), which features articles related to research in and the practice of clinical cardiac electrophysiology and the diagnosis and management of […]